.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Federal Trade Commission
Julphar
Chinese Patent Office
Novartis
Fuji
Deloitte
Queensland Health
Colorcon
UBS

Generated: November 21, 2017

DrugPatentWatch Database Preview

Salix Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SALIX PHARMS INC, and what generic alternatives to SALIX PHARMS INC drugs are available?

SALIX PHARMS INC has one approved drug.

There are eight US patents protecting SALIX PHARMS INC drugs and there have been three Paragraph IV challenges on SALIX PHARMS INC drugs in the past three years.

There are seventy patent family members on SALIX PHARMS INC drugs in thirty-two countries.

Summary for Salix Pharms Inc

International Patents:70
US Patents:8
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Salix Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix Pharms Inc
RELISTOR
methylnaltrexone bromide
TABLET;ORAL208271-001Jul 19, 2016► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SALIX PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
methylnaltrexone bromide
Tablets150 mg
RELISTOR
9/6/2016
methylnaltrexone bromide
Injection8 mg/0.4 mL
RELISTOR
9/8/2015
methylnaltrexone bromide
Injection12 mg/0.6 mL
RELISTOR
7/22/2015

Non-Orange Book Patents for Salix Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,972,954 Use of methylnaltrexone and related compounds► Subscribe
8,247,425Peripheral opioid receptor antagonists and uses thereof► Subscribe
8,455,644Peripheral opioid receptor antagonists and uses thereof► Subscribe
8,822,490Peripheral opioid receptor antagonists and uses thereof► Subscribe
6,608,075 Use of methylnaltrexone and related compounds► Subscribe
6,274,591 Use of methylnaltrexone and related compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Salix Pharms Inc Drugs

Country Document Number Estimated Expiration
South Korea101566675► Subscribe
Peru00632013► Subscribe
European Patent Office2356119► Subscribe
Eurasian Patent Organization201270741► Subscribe
China102918039► Subscribe
Georgia, Republic ofP201606550► Subscribe
China102307874► Subscribe
Japan2011190259► Subscribe
World Intellectual Property Organization (WIPO)2010039851► Subscribe
Japan6143409► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Queensland Health
Daiichi Sankyo
UBS
Farmers Insurance
Novartis
Federal Trade Commission
Moodys
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot